Analytical Data
-
Gene name
HLA-B*07:02&B2M&HPV16 E7(KPTLKEYVL) Monomer
- Application
-
Alternative Names
HLA-B*0702 & B2M & HPV16 E7 (KPTLKEYVL)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
QDK63242.1 (G25-V309)&P61769
-
Expression Region
QDK63242.1 (G25-V309)&P61769 (I21-M119)&KPTLKEYVL
-
Molecular Weight
42-45 kDa and 12 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-B*07:02, beta-2-microglobulin (B2M), and HPV16 E7 (KPTLKEYVL) monomer recombinant protein is significant in the field of immunology and cancer research. Human Papillomavirus (HPV), particularly HPV16, is a well-established etiological agent of cervical and other anogenital cancers. The E7 oncoprotein of HPV16 plays a crucial role in cell transformation and proliferation by interacting with host cell proteins. HLA-B*07:02 is a major histocompatibility complex (MHC) class I molecule that presents endogenous peptides, including viral antigens, to CD8+ cytotoxic T lymphocytes. The specific peptide KPTLKEYVL, derived from the E7 protein, is known to be a potent T-cell epitope that elicits immune responses in HPV-infected individuals. By creating a recombinant protein that includes HLA-B*07:02, B2M, and the HPV16 E7 peptide, researchers aim to investigate the structure and function of this complex, assess its stability, and understand how it interacts with T-cell receptors. This research has implications for developing targeted immunotherapies and vaccines that could enhance anti-viral and anti-tumor immunity in patients with HPV-associated malignancies. Understanding how this monomeric protein functions at a molecular level can contribute to improved strategies for diagnosing, treating, and preventing HPV-related diseases.
